These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 34284582)
1. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer. Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582 [TBL] [Abstract][Full Text] [Related]
2. tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel. Ma Y; Li R; Dong Y; You C; Huang S; Li X; Wang F; Zhang Y Int J Nanomedicine; 2021; 16():789-802. PubMed ID: 33568906 [TBL] [Abstract][Full Text] [Related]
3. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells. Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905 [TBL] [Abstract][Full Text] [Related]
4. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells. Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697 [TBL] [Abstract][Full Text] [Related]
5. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles. Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300 [TBL] [Abstract][Full Text] [Related]
6. Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment. Kang T; Zhu Q; Jiang D; Feng X; Feng J; Jiang T; Yao J; Jing Y; Song Q; Jiang X; Gao X; Chen J Biomaterials; 2016 Sep; 101():60-75. PubMed ID: 27267628 [TBL] [Abstract][Full Text] [Related]
7. Lysosome-Independent Intracellular Drug/Gene Codelivery by Lipoprotein-Derived Nanovector for Synergistic Apoptosis-Inducing Cancer-Targeted Therapy. Wang W; Chen K; Su Y; Zhang J; Li M; Zhou J Biomacromolecules; 2018 Feb; 19(2):438-448. PubMed ID: 29334216 [TBL] [Abstract][Full Text] [Related]
8. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy. Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317 [TBL] [Abstract][Full Text] [Related]
9. Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release. Stras S; Howe A; Prasad A; Salerno D; Bhatavdekar O; Sofou S Mol Pharm; 2020 Jan; 17(1):118-131. PubMed ID: 31825626 [TBL] [Abstract][Full Text] [Related]
10. pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer. Wan X; Liu C; Lin Y; Fu J; Lu G; Lu Z Drug Deliv; 2019 Dec; 26(1):470-480. PubMed ID: 30957572 [TBL] [Abstract][Full Text] [Related]
11. Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. Hu Q; Gao X; Gu G; Kang T; Tu Y; Liu Z; Song Q; Yao L; Pang Z; Jiang X; Chen H; Chen J Biomaterials; 2013 Jul; 34(22):5640-50. PubMed ID: 23639530 [TBL] [Abstract][Full Text] [Related]
12. Unveiling the potential of ursolic acid modified hyaluronate nanoparticles for combination drug therapy in triple negative breast cancer. Sharma R; Yadav V; Jha S; Dighe S; Jain S Carbohydr Polym; 2024 Aug; 338():122196. PubMed ID: 38763723 [TBL] [Abstract][Full Text] [Related]
13. Tumor-Targeting Micelles Based on Linear-Dendritic PEG-PTX Zhang Y; Lu Y; Zhang Y; He X; Chen Q; Liu L; Chen X; Ruan C; Sun T; Jiang C Mol Pharm; 2017 Oct; 14(10):3409-3421. PubMed ID: 28832164 [TBL] [Abstract][Full Text] [Related]
14. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004 [TBL] [Abstract][Full Text] [Related]
15. Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells. Zhang BB; Chen XJ; Fan XD; Zhu JJ; Wei YH; Zheng HS; Zheng HY; Wang BH; Piao JG; Li FZ Acta Pharmacol Sin; 2021 May; 42(5):832-842. PubMed ID: 33824461 [TBL] [Abstract][Full Text] [Related]
16. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer. Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758 [TBL] [Abstract][Full Text] [Related]
17. Combined chemotherapy for triple negative breast cancer treatment by paclitaxel and niclosamide nanocrystals loaded thermosensitive hydrogel. Zhao D; Hu C; Fu Q; Lv H Eur J Pharm Sci; 2021 Dec; 167():105992. PubMed ID: 34517104 [TBL] [Abstract][Full Text] [Related]
18. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin. Rui M; Xin Y; Li R; Ge Y; Feng C; Xu X Mol Pharm; 2017 Jan; 14(1):107-123. PubMed ID: 27982602 [TBL] [Abstract][Full Text] [Related]
19. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Yu DH; Lu Q; Xie J; Fang C; Chen HZ Biomaterials; 2010 Mar; 31(8):2278-92. PubMed ID: 20053444 [TBL] [Abstract][Full Text] [Related]